FINWIRES · TerminalLIVE
FINWIRES

Baird Downgrades Karyopharm Therapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $15

By

Karyopharm Therapeutics (KPTI) has an average rating of overweight and mean price target of $9.83, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

Research

Oppenheimer Downgrades Capricor Therapeutics to Perform From Outperform, Price Target is $54

Capricor Therapeutics (CAPR) has an average rating of overweight and mean price target of $29.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $3.00, Change: $-3.57, Percent Change: -54.34%

$CAPR
Research

BofA Securities Downgrades Cincinnati Financial to Neutral From Buy, Lowers Price Target to $193 From $197

Cincinnati Financial (CINF) has an average rating of overweight and mean price target of $190, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $179.11, Change: $-2.23, Percent Change: -1.23%

$CINF
Research

RBC Cuts Price Target on Wingstop to $200 From $225, Keeps Outperform Rating

Wingstop (WING) has an average rating of buy and mean price target of $214.62, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$WING